These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11416657)

  • 1. Angiotensin II Antagonists in the Treatment of Hypertension: More Similarities Than Differences.
    Conlin PR
    J Clin Hypertens (Greenwich); 2000 Jul; 2(4):253-257. PubMed ID: 11416657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympatho-inhibitory properties of various AT1 receptor antagonists.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren: renin inhibitor for hypertension management.
    Cheng JW
    Clin Ther; 2008 Jan; 30(1):31-47. PubMed ID: 18343241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II antagonists in the treatment of hypertension-effective and efficient?
    Müller-Nordhorn J; Willich SN
    Herz; 2003 Dec; 28(8):733-7. PubMed ID: 14689108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction--the role of angiotensin II antagonists.
    Conlin PR
    Int J Clin Pract; 2005 Feb; 59(2):214-24. PubMed ID: 15854200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.
    Oparil S; Silfani TN; Walker JF
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):287-94. PubMed ID: 15752958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptor antagonists role in arterial hypertension.
    Hernández-Hernández R; Sosa-Canache B; Velasco M; Armas-Hernández MJ; Armas-Padilla MC; Cammarata R
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S93-9. PubMed ID: 11986904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT(1)-receptor blockers: differences that matter.
    Gradman AH
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Missed Opportunity: Our Failure to Control Hypertension Optimally.
    Gifford RW
    J Clin Hypertens (Greenwich); 2000 Jan; 2(1):21-24. PubMed ID: 11416621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Hypertension: Contributions of Clinical Trials.
    Roel JP; Grimm RH
    J Clin Hypertens (Greenwich); 2000 May; 2(3):198-203. PubMed ID: 11416647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Injectable, Wound-Adapting, Self-Healing Hydrogel for Fibroblast Growth Factor 2 Delivery System in Tissue Repair Applications.
    Chen G; Ren J; Deng Y; Wu X; Huang J; Wang G; Zhao Y; Li J
    J Biomed Nanotechnol; 2017 Dec; 13(12):1660-1672. PubMed ID: 29490754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sensitization to casein and beta-lactoglobulin (BLG) in children with cow's milk allergy (CMA)].
    Nakano T; Shimojo N; Morita Y; Arima T; Tomiita M; Kohno Y
    Arerugi; 2010 Feb; 59(2):117-22. PubMed ID: 20212353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.